## Analysis of Pertussis Immunology and Clinical Management ### Key Point: Pertussis Vaccine Immunity Duration **Acellular pertussis vaccine (aP) provides protection for approximately 5–10 years**, not lifelong immunity. This is why booster doses (Tdap) are recommended at adolescence (11–12 years) and every 10 years in adulthood, or after each pregnancy (maternal Tdap at 27–36 weeks). Whole-cell vaccine (wP) historically provided longer-lasting immunity but is no longer used due to adverse effects. ### High-Yield: Why Options 1, 2, and 3 Are Correct | Aspect | Details | |--------|----------| | **First-line antibiotic** | Erythromycin (or azithromycin) for 5 days; also used for prophylaxis in unvaccinated/incompletely vaccinated contacts | | **Paroxysmal stage** | Lasts 2–8 weeks (range up to 12 weeks); this is when the characteristic "whooping" cough and post-tussive vomiting occur; most contagious phase | | **Toxin-mediated pathology** | Pertussis toxin (PT) and tracheal cytotoxin cause mucosal damage, cilia destruction, and systemic effects (lymphocytosis, encephalopathy); these toxins drive severe disease in infants | ### Clinical Pearl: Vaccination Waning Immunity The shift from whole-cell to acellular pertussis vaccine improved safety but reduced durability of immunity. This explains the resurgence of pertussis in adolescents and adults in highly vaccinated populations — they are no longer immune despite prior vaccination. ### Warning: Common Exam Trap Students often confuse "acellular vaccine provides good protection" with "acellular vaccine provides lifelong protection." The former is true; the latter is false. Waning immunity is a well-documented phenomenon and is the reason for booster recommendations.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.